Combinational endothelial strategies show promise for multi-stage cancer treatment.

Testing on a mouse model shows an inhibitor targeting VEGFRs in endothelial cells is effective against early stage angiogenic lesions. A kinase inhibitor is shown to block the growth of end-stage tumors, recruiting pericytes for disruption of tumor vascularity. The conclusion suggests that combinatorial targeting promises treatment for multiple stages in tumorigenesis.